Ownership
Private
Employees
~100
Therapeutic Areas
NeurologyPsychiatry
Stage
Phase 3
Modalities
Small molecule

AriBio General Information

AriBio is developing AR1001, a small molecule targeting phosphodiesterase 5, for Alzheimer's Disease. Phase 2 results showed no significant change in primary endpoints but suggested potential benefits in subgroups. Phase 3 trials are ongoing, with completion expected in December 2025.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
,
South Korea

Drug Pipeline

AR1001
Phase 3
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to AriBio's pipeline data

Book a demo

Key Partnerships

No partnerships listed

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

AriBio Funding

Deal TypeDateAmountStatusStage
Later Stage VCFeb 18, 2022$83.6MCompletedPhase 3
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view AriBio's complete valuation and funding history, request access »